Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Rating of “Moderate Buy” by Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given a consensus rating of “Moderate Buy” by the ten analysts that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $13.78.

Several equities research analysts have weighed in on TEVA shares. Piper Sandler raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $12.00 to $19.00 in a report on Monday, February 12th. The Goldman Sachs Group raised their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Barclays raised their price objective on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a research note on Friday, March 8th.

Teva Pharmaceutical Industries Trading Up 0.8 %

TEVA stock opened at $13.19 on Friday. Teva Pharmaceutical Industries has a 1-year low of $7.09 and a 1-year high of $14.47. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. The company has a market capitalization of $14.79 billion, a price-to-earnings ratio of -28.06, a PEG ratio of 1.59 and a beta of 1.05. The business has a 50 day simple moving average of $13.45 and a two-hundred day simple moving average of $11.21.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The company had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. Research analysts anticipate that Teva Pharmaceutical Industries will post 2.28 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 31,766 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares of the company’s stock, valued at $132,062.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total value of $1,352,000.00. Following the sale, the executive vice president now owns 382,590 shares of the company’s stock, valued at $5,172,616.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 390,738 shares of company stock valued at $5,132,766. 0.62% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently modified their holdings of TEVA. Money Concepts Capital Corp acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth $25,000. Quilter Plc acquired a new position in Teva Pharmaceutical Industries in the first quarter worth $3,103,125,000. Tower Research Capital LLC TRC boosted its stake in Teva Pharmaceutical Industries by 1,729.5% in the third quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock worth $39,000 after purchasing an additional 3,580 shares in the last quarter. US Bancorp DE boosted its stake in Teva Pharmaceutical Industries by 36.5% in the fourth quarter. US Bancorp DE now owns 3,828 shares of the company’s stock worth $40,000 after purchasing an additional 1,023 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in Teva Pharmaceutical Industries by 92.3% in the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock worth $46,000 after purchasing an additional 2,180 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.